Industry Soldiers On With US Device Tax Fight
This article was originally published in Clinica
Executive Summary
The medtech industry’s lobbying against the device excise tax has continued unabated despite the recent two-year suspension of the tax.
You may also be interested in...
Lobbyists Again Coordinate Device Tax Attack
AdvaMed and MDMA, two rivaling lobby groups, have again come together against a common enemy: the Obamacare medical device excise tax. The groups simultaneously released survey results that argue that permanently repealing the tax would be a boon for their member companies and innovation.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.